1	Alternative Approaches for Monitoring and Evaluation of Lymphatic Filariasis Following
2	Mass Drug Treatment with Ivermectin, Diethylcarbamazine and Albendazole in East New
3	Britain Province, Papua New Guinea
4	
5	Running title: Monitoring and Evaluation for LF following MDA-IDA in Papua New
6	Guinea
7	Krufinta Bun ¹ , Benedict Mode ² , Melinda Susapu ³ , Catherine Bjerum ¹ , Michael Payne ¹ , Daniel
8	Tisch ¹ , Makoto Sekihara ⁵ , Emanuele Giorgi ⁶ , Gary J. Weil ⁸ , Peter U Fischer ⁸ , Leanne Robinson ⁷ ,
9	Moses Laman ⁴ , Christopher L. King ^{1,9,*}
10	
11	Affiliations
12	¹ Center for Global Health and Disease, Department of Pathology, Case Western Reserve
13	University, Cleveland OH USA
14	² Provincial Health Department, East New Britain Province, Papua New Guinea
15	⁴ Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
16	³ Papua New Guinea Department of Health, Port Moresby, Papua New Guinea
17	⁵ Japan International Cooperation Agency (JICA)
18	⁶ Centre for Health Informatics, Computing and Statistics, Lancaster University, Lancaster, UK

- ⁸ Infectious Diseases Division, Department of Medicine, Washington University, St. Louis MO,
- 21 USA,
- ⁹ Veterans Affairs Medical Center, Cleveland, OH.
- 23 *Christopher L. King, Corresponding author <u>cxk21@case.edu</u>

24 Abstract

25 Background

- 26 WHO recommends two annual rounds of mass drug administration (MDA) with ivermectin,
- 27 diethylcarbamazine, and albendazole (IDA) for lymphatic filariasis (LF) elimination in treatment
- 28 naïve areas that are not co-endemic for onchocerciasis such as Papua New Guinea (PNG).
- 29 Whether two rounds of MDA are necessary or sufficient and the optimal sampling strategies and
- 30 endpoints for stopping MDA remain undefined.

31 Methods and Findings

32 Two cross-sectional studies were performed, one at baseline in 2019 before MDA-IDA, and 12

33 months post-MDA-IDA. Pre-MDA, we selected 49 sentinel villages for LF in East New Britain

34 Province (ENBP, PNG) and randomly sampled ~100 individuals/village of approximately equal

number of children 6-9 years (N=1,906), and those \geq 10 years (N=2,346) using population

36 proportionate and purposeful sampling. LF infection was assessed by tests for circulating filarial

antigenemia (CFA) and microfilariae (Mf). Children ages 6-9, 1.9% (37/1,906, range 0-21.6%)

were CFA positive at baseline, and 0.3% (5/1,906; range 0-7.8%) were Mf positive. Individuals

 ≥ 10 years, 7.5% (176/2,346, range 0-52%) were CFA positive, and 2.0% (47/2,346, range 0-

40 36%) were Mf positive. Twenty-four of 49 clusters were CFA \geq 2%, and 14 had Mf prevalence

41 \geq 1%. Post-MDA (82% coverage), 47 clusters were selected based on geospatial modeling

42 (N=4,610), of which 38 had >2% CFA compared to 24 identified at baseline. In the 24 villages

- 43 evaluated pre- and post-MDA, we stratified the impact of MDA-IDA on children 6-9 and adults
- 44 \geq 18 years. Children had a 34% reduction in CFA prevalence and complete Mf clearance. Adults

45	had a 39% reduction in CFA prevalence and a 96% reduction in Mf prevalence. Post-MDAx1
46	showed no villages that were Mf positive in two of four districts.
47	
48	Conclusions
49	Geospatial modeling was more effective in sampling high-risk sites for LF than population-
50	proportional sampling. The low LF prevalence in children and slight reduction of CFA
51	prevalence limits its utility as a biomarker for LF elimination in children. A single round of
52	MDA with IDA with high coverage was sufficient to reach elimination targets in villages with
53	low baseline LF prevalence. Areas with higher baseline prevalence will require additional rounds
54	of MDA, but this could be targeted to smaller evaluation units to reduce cost.
55	
56	
57	Trial registration
58 59	This study is registered at Clinicaltrials.gov under the number NCT04124250
60	Author Summary
61	
62	Why was this study done?
63	• WHO has targeted lymphatic filariasis (LF) for global elimination as a public health
64	problem using mass drug administration (MDA) as the primary intervention strategy.
65	• The WHO recently modified recommendations for MDA of LF with a combination of
66	three co-administered drugs: ivermectin, diethylcarbamazine, and albendazole. This study
67	examined the impact of one round of MDA on LF infection parameters in Papua New

- 68 Guinea that had not previously received MDA for LF and examined new methodologies69 for monitoring and surveillance.
- What did the researcher do and find? 70 Before MDA, we randomly sampled sentinel clusters (villages) using population 71 proportional sampling of equal numbers of children 6-9 years and older children and 72 adults using well-established LF infection parameters. Post-MDA, we selected sentinel 73 villages using a geospatial modeling design and focused on sampling adults. 74 Population-proportional sampling underestimated the overall LF infection because the 75 76 infection was more common in less-densely populated rural areas. Sampling children 6-9 years of age was inefficient because of very low infection rates in this age group. 77 Geospatial modeling was more effective than population proportional sampling for 78 79 selecting areas at high risk for LF. One round of MDA with high coverage was highly effective for reducing microfilaremia prevalence to very low levels in most sampled 80 villages, but CFA prevalence decreased less dramatically. 81 What do these findings mean? 82 Geospatial modeling and sampling adults for microfilaria are preferred methods for 83 monitoring the impact of MDA with IDA. 84 Results from this study suggest that one round of high-coverage MDA may be sufficient 85 to interrupt LF transmission in areas with low baseline prevalence. Additional rounds of 86 MDA can then be targeted to areas with higher LF prevalence, thus reducing program 87 costs. This strategy requires high-quality baseline surveillance to capture the focality of 88 LF infection and high-quality MDA. This approach may be especially useful in areas like 89 90 Papua New Guinea, where MDA is logistically challenging.
 - 5

91 Introduction

92	Lymphatic filariasis (LF) is a disease caused by parasitic nematodes transmitted by
93	mosquitoes. The infection leads to a spectrum of clinical outcomes that range from asymptomatic
94	microfilaremia (parasite larvae circulating in the blood) to hydrocele, lymphedema, and
95	elephantiasis [1]. Lymphatic filariasis is caused by the nematodes Wuchereria bancrofti, Brugia
96	malayi and Brugia timori, of which W. bancrofti accounts for over 90% of infection worldwide
97	[2]. The World Health Organization (WHO) currently estimates that 883 million people in 44
98	countries are at risk for LF"L/o: and that 15 million are disfigured and incapacitated by the
99	disease [3]. The WHO started the Global Program to Eliminate Lymphatic Filariasis (GPELF) in
100	2000 with a goal to eliminate LF by 2020 [2], which was later revised to 2030 [4]. The
101	elimination strategy comprises community-wide mass drug administration (MDA) in endemic
102	areas based on administrative units that often include a mix of areas with high and low
103	endemicity. Mass drug treatment comprises annual single-dose therapy of albendazole (ALB)
104	combined with diethylcarbamazine (DEC) in countries not co-endemic for onchocerciasis, and
105	ALB combined with ivermectin (IVM) in onchocerciasis co-endemic countries in sub-Saharan
106	Africa that are not co-endemic for Loa loa [5]. Areas in Africa that are co-endemic for Loa loa
107	and have high parasite loads should receive ALB only. The LF elimination strategy also includes
108	morbidity management of advanced clinical cases. To interrupt transmission, the current GPELF
109	strategy recommends MDA with a minimum effective coverage of $\geq 65\%$ for up to five annual
110	rounds of MDA [6]. This strategy has been highly successful in many LF endemic countries,
111	resulting in 740 million people no longer requiring MDA. This amounts to a 52% reduction in
112	the at-risk population worldwide [7]. However, this approach has been less successful in other
113	LF endemic areas because of poor uptake of drugs in people with the highest risk of infection

(e.g. adult men, migrants, and pregnant women), logistical challenges for drug delivery, andlimited efficacy of the two-drug MDA regimens.

116	In 2017, the WHO endorsed the use of a single co-administered IVM plus DEC plus ALB
117	(referred to as IDA) for LF elimination in many areas outside of Africa because it was more
118	effective than DEC plus ALB [8-13]. IDA is recommended in LF endemic settings that are
119	eligible for drug combinations that include DEC; i) where onchocerciasis is not co-endemic, ii)
120	that have not yet started MDA, iii) that have received fewer than four effective rounds of MDA,
121	or iv) in areas where MDA results have been suboptimal [14]. Currently, the WHO recommends
122	two annual rounds of MDA with IDA in eligible countries with at least 65% epidemiological
123	coverage. More data are needed on whether two rounds are necessary or sufficient to interrupt
124	LF transmission.

One challenge associated with MDA that is especially important in areas that distribute 125 126 IDA is knowing when infection prevalence has been reduced to levels that no longer can support sustained transmission so that MDA can be stopped. While IDA is very efficient for clearing 127 microfilariae (Mf) from the blood, circulating filarial antigen (CFA) persists because IDA 128 129 sterilizes but does not kill all adult worms [9]. The current MDA stopping protocol uses 130 transmission assessment surveys (TAS) to detect CFA in children 6-7 years of age as an 131 indicator of recent transmission [15]. However, TAS can be insensitive to ongoing LF 132 transmission in areas where infection prevalence is much lower in children than adults. Before 133 proceeding to TAS, programs perform pre-TAS surveys to assess whether CFA prevalence is 134 less than 2% or Mf prevalence is <1% in one sentinel and one spot-check site within an evaluation unit. However, the focal distribution of LF represents an important limitation to this 135 strategy; pre-TAS surveys may miss persistent infection when only some sites are sampled in 136

137	large evaluation units. Another problem with pre-TAS and TAS surveys based on the detection
138	of CFA is that the persistence of CFA after IDA may require MDA to be continued long after Mf
139	prevalence has been reduced to levels that cannot sustain transmission.
140	Cognizant of these challenges, the Task Force for Global Health (with external input)
141	developed a new monitoring and evaluation approach to evaluate the impact of MDA with
142	IDA. We applied this approach to East New Britain Province (ENBP), which had yet to
143	implement province-wide MDA for LF. Here, we aim to i) assess the impact of one round of
144	IDA on LF infection parameters, ii) provide evidence to justify adopting new elimination
145	criteria and endpoints using IDA and iii) optimize sampling strategies to capture better the
146	focality of LF in the population and to demonstrate the elimination of LF.
147	

148 Methods

149 Study Site

East New Britain Province (ENBP, population approximately 376,566) comprises the eastern
half of the island of New Britain in PNG (5° 10′ 0″ S, 151° 45′ 0″ E). It is divided into four
districts: Gazelle, Pomio, Kokopo, and Rabaul (Figure 1, Table 1). Most people reside in the
less mountainous northeastern part of the province. Cocoa, copra, and palm oil are the major
cash crops. Rabaul and Kokopo districts are more urbanized, with more modern structures

- 155 (housing with window screens), easy access to paved roads, and electricity. Gazelle and
- 156 Pomio are rural districts with less infrastructure.



168 Figure 1. Map of East New Britain Province.

169

170

172 Ethical approval

173	The protocol was approved by the Medical Research Advisory Council of PNG (MRAC
174	19.14) and Case Western Reserve University IRB (STUDY20191141). Individual written
175	informed consent was provided by adults aged 18 years and older. If the individuals could not
176	read or write, a village member who could read or write served as a witness and cosigned the
177	informed consent form. Children's participation required the consent of their parents and
178	documented assent for children older than 12 years of age.

179 Mass Drug Administration

180 In November 2019 MDA with IDA (MDA-IDA) was conducted throughout the province.

181 Before MDA, community health workers (CHW) were essential in establishing strong

182 community engagement through meetings (known as *Toksave*), and training community

183 distributors. MDA was distributed over 3 weeks to facilitate travel to remote areas, better

184 capture mobile populations, and provide time for mop-up. The whole MDA process was

185 coordinated by a highly engaged LF/NTD task force in the province that involved community

186 leaders and other stakeholders, ensuring campaign success.

187 Study design and village selection

The primary sampling unit was the village. In September and October 2019, we conducted a
baseline cross-sectional survey of 30 villages in ENBP using population proportionate
random sampling (PPS). Five additional villages suspected to have high LF rates were
purposively selected by the ENBP provincial health LF Taskforce. Fourteen additional
villages were added to improve sampling in rural areas with lower population densities and

higher LF risk. The villages selected by PPS in each district (Kokopo, Rabaul, Pomio, and
Gazelle) were proportionate to the population size of the districts, with Gazelle having the
most selected villages and Rabaul having the least (Table 1).

Since the Anopheles mosquitos transmit LF in PNG the sample size was powered to detect a 196 197 2% CFA threshold for each of two groups; i) children aged 6-9 years old and other community members ≥ 10 years, and ii) during the post-MDA survey children aged 6-9 years 198 old and other community members ages ≥ 18 years. The post-MDA target population and 199 sample size were adjusted based on WHO interim guidelines of a 1% Mf threshold in adults 200 ≥18 years with a 95% confidence interval to assess the impact of IDA (IDA Technical Report 201 202 2022). The selected households within each cluster are adapted from the WHO guidelines for evaluating coverage surveys and monitoring [16]. Fifty households were randomly selected 203 from a starting point in the center of the community using a pen or spin bottle. Before the 204 205 survey, each household within the villages was assigned a number with the help of a village recorder or leader. Household numbers were written on cut paperboard placed in a large jar, 206 207 and we randomly drew numbers until 50 households were selected. If a cluster of households 208 consisted of family groups, the cluster was considered 'one' household unit. All members of the 50 households were surveyed for children aged 6-9 years and individuals ≥ 10 years until 209 100 participants were reached (50 children and 50 adults). Demographic surveys recorded the 210 number of people per household, the age and sex of individuals, the number of children ages 211 6-9, and the number of persons ≥ 10 years of age. 212

213 Socio-economic assessment

At baseline, we compiled a socioeconomic impact (SEI) score for each village by assessing 214 215 access to potable water, the use of window screens, and the level of education for each 216 household. In calculating the SEI scores, we counted 1 point if a household had access to a water tank or pipe (0 for river/stream or public pump/well), and 1 point if window screens 217 were used (0 for no screens). In scoring educational status, each adult (18 years or older) 218 219 received a score based on their highest level of education attained; 3 points for college or vocational training, 2 points for high school graduates, 1 point for an 8th-grade education, and 220 221 a score of 0 if the adult had not attended school through the 8th-grade. The 222 composite educational score was computed by taking the average score of each adult in the household. The total SEI score for each household was obtained by adding the educational 223 average to the water and screen scores. To get the SEI score for each village, we averaged all 224 the households in that village. Higher SEI scores indicate higher socioeconomic status. We 225 also computed 95% confidence intervals and ranges for village SEI scores. The SEI scores 226 227 were used in the geostatistical model described below.

228 Coverage survey

A cluster sampling approach was applied to determine drug coverage after one round of MDA 229 230 [16]. The primary sampling unit was local level government (LLG) within each of the 4 districts, and each LLG contained wards that consisted of many villages. The Rotary Against 231 Malaria (RAM) survey for 2016 was used as the denominator of the village population. In this 232 survey, 8 LLGs or clusters in each of the 4 districts were selected by population proportionate 233 sampling (PPS) which were: Gazelle Central Rural (Gazelle), Lasul Baining Rural (Gazelle), 234 235 Vunadirir Toma Rural (Gazelle), Bitapaka Rural (Kokopo), Kokopo Vunamami Urban 236 (Kokopo), East Pomio Rural (Pomio), Balanataman Rural (Rabaul) and Rabaul Urban

(Rabaul). Gazelle Central Rural LLG was divided into 3 independent clusters because of the
large population size relative to the rest of LLGs in ENBP. PPS then selected the villages
within the LLGs for the coverage surveys. Across the LLGs, 45 villages were surveyed for
drug coverage. Twenty-five of the 45 villages were in the Gazelle district, 10 in Kokopo, 5 in
Pomio and 5 in Rabaul. Of the 45 villages surveyed, 15 (33.3%) were included in the baseline
LF prevalence survey.

243 Selection of study sites at 1-year post-MDA

244 The post-MDA survey used model-based geostatistics (MBG) to select 50 villages with a high

probability of having a CFA prevalence >2% (Table 1). Twenty-four of the 50 selected

villages had CFA >2% in the baseline survey. Approximately 100 individuals were surveyed

in each village. Of the 23 newly selected villages surveyed, only adults ≥ 18 years were

sampled because of the low infection prevalence in young children in the baseline surveys in

249 most villages. In the 24 villages sampled pre- and post-MDA, 15 villages had CFA

250 prevalence >2% in children 6-9 years of age at baseline. Children in these 15 villages were

resampled post-MDA as follows: \sim 50 children ages 6-9 and \sim 50 adults \geq 18 years to examine

the impact of MDA on LF infection parameters in children compared to adults.

253 **Procedures**

Fingerstick blood samples were collected during the surveys for CFA testing with Filariasis Test
Strips (FTS) (Alere, Scarborough, ME, USA) according to the manufacturer's protocol. Tests
with no control line were invalid and repeated. The FTS detects a biomarker for infection with *W. bancrofti* (Wb) adult worms, and it has a high sensitivity for detecting persons with
microfilaremia. In community studies in PNG, all Mf-positive individuals had positive FTS

259	results [17]. In this study, persons with positive FTS results were tested for Mf with 60-µl thick
260	blood smears prepared from fingerstick samples collected between 9 PM and 1 AM, as
261	previously described [17]. Two microscopists reviewed the slides. If Mf counts were highly
262	discordant or one reader identified Mf and the other did not, a third reader reviewed the slide.
263	
264	Data acquisition and management
265	The study used an electronic data capture (EDC) system using Epi Info TM (Centers for Disease
266	Control) software to capture and transfer data to a REDCap database (v11.0.3, Vanderbilt
267	University). The data were entered by designated, trained members of the PNG research team on
268	the day of enrollment. A parallel participant key (separate from the REDCap database and
269	maintained at PNG Institute for Medical Research) linked study ID numbers with personal
270	identifying information, such as name and date of birth. The participant key was not shared with
271	Case Western Reserve University investigators or staff.
272	
273	Geospatial and Statistical analysis
274	The geostatistical methods used to sample the number of clusters at one-year post-MDA-IDA
275	followed adaptive geostatistical designs [18]. The approach involved sampling or selecting
276	locations given previous infection data. The methodological framework includes prevalence data
277	modelled to describe the number of people infected with a particular disease or outcome, at a
278	given location, in a specific region of interest with a vector of associated covariates. The model
279	assumes a spatial Gaussian process to measure the outcome of interest (i.e., disease prevalence)
280	given a set of covariates independent from each other at specific locations. The covariates in the
281	model were environmental exposures and socio-economic impact score using the PrevMap
282	package [19]. Records with complete spatial information correspond to 47 of the 49 clusters. The
	14

283	model accounts for the spatial correlation between clusters based on their proximity in space,
284	whereby closer clusters are assumed to be more correlated than clusters further apart. The current
285	analysis also modeled the association between locations on distinct land masses through the
286	Euclidean distance - i.e., the ordinary "straight-line" distance. The predictions were carried out
287	on a 1 by 1 km regular grid. Grid locations whose distance from the closest data-locations is
288	larger than 15 km are excluded from the predictions. This is because we estimate a scale of the
289	spatial correlation of about 15 km; hence, the data bear very little information on the prevalence
290	at those locations. There were 748 clusters in ENBP of which we selected 49 that had the
291	probability of exceeding 2% CFA prevalence threshold (see Supplementary Methods).
292	Descriptive statistics were calculated as frequencies and proportions for categorical variables \pm
292 293	Descriptive statistics were calculated as frequencies and proportions for categorical variables \pm 95% confidence intervals. For demographic variables, median and interquartile ranges, or mean
292 293 294	Descriptive statistics were calculated as frequencies and proportions for categorical variables \pm 95% confidence intervals. For demographic variables, median and interquartile ranges, or mean \pm SD were used. Comparisons between treatment groups for demographic and infection variables
292 293 294 295	Descriptive statistics were calculated as frequencies and proportions for categorical variables \pm 95% confidence intervals. For demographic variables, median and interquartile ranges, or mean \pm SD were used. Comparisons between treatment groups for demographic and infection variables were performed using chi-square and Fisher's exact tests (as appropriate) for categorical
292 293 294 295 296	Descriptive statistics were calculated as frequencies and proportions for categorical variables ± 95% confidence intervals. For demographic variables, median and interquartile ranges, or mean ± SD were used. Comparisons between treatment groups for demographic and infection variables were performed using chi-square and Fisher's exact tests (as appropriate) for categorical variables using SAS (v 9.4, SAS Institute).

298 **Results**

The evaluation unit in PNG is the province, although the districts better capture the province's considerable geographic and social heterogeneity. Overall, 4,252 participants were enrolled for the baseline survey and 4,611 for the one-year post-MDA-IDA survey. **Table 1** describes the population characteristics and sampling design pre- and post-MDA-IDA.

Table 1. Baseline and one year post MDA-IDA impact survey characteristics.

Survey time	Cluster type	Age category	No. sampled	Mean Age±SD
				(Range)
Baseline	Random	Children	1,121ª	7.4±1.2
	N=30			(6-9)
		Adults	1,449 ^b	29.6±14.4)
				(10-77)
	Purposive	Child	785 ^a	7.4±1.2)
	N=19			(6-9)
		Adults	906 ^b	29.9±14.3)
				(10-72)
	All sites	Child	1,906ª	7.4±1.1
	N=49			(6-9)
		Adults	2,346 ^b	29.6±14.4)
				(10-77)
One year Post-	Repeat	Children	417ª	7.6±1.2
MDA	villages from			(6-9)
	Baseline N=24	Adults	2,015°	34.8±14.1
				(10-88)
	Geo-spatial	Children	278ª	7.6±1.3
	Selection			(6-9)
	N=23	Adults	1,901°	34.7±13.5
				(18-81)

	All sites N=47	Children	695 ^a	7.6±1.2
				(6-9)
		Adults	3,916°	34.8±13.8
				(10-88)

^a 6-9 years of age

 $b \ge 10$ years

 $^{\rm c} \ge 18$ years

308

309 Baseline LF infection parameters

310 At baseline, 4,252 participants in 49 clusters (villages) were examined for LF infection,

of which 1,906 were children aged 6-9 years, and 2,346 were individuals aged \geq 10 years

312 (Tables 1, 2 a and b). Females accounted for 48% of the 6-9 years sampled and 61% of those \geq

313 10 years. Among the 6-9-year-olds, 1.9 % (95% CI 1.4-2.7; 37/1,906) were CFA positive

prevalence, and 0.3% (95% CI 0.09-0.61; 5/1,906) were Mf positive. Among those ≥ 10 years,

315 7.5% (95% CI 6.5-8.6; 176/2,346) were CFA positive and 2.0% (95%CI 1.5-2.7; 47/2,347) Mf

positive. Circulating filarial antigen and Mf prevalence increased with age, with the highest

prevalence in men between 21 and 30 (Figure 2). Combining all groups, twenty-four (48.9%) of

the 49 villages had $\geq 2\%$ CFA, and 14 met the $\geq 1\%$ Mf threshold (**Supplemental Table 1A**).

Based on WHO criteria, these are thresholds indicative of ongoing LF transmission. The CFA

prevalence <2.0% among 6-9-year-olds would suggest that ENBP might not have ongoing LF

transmission based on the WHO transmission assessment survey (TAS) of lower primary school-

aged children 6-7 years of age using a 2% CFA threshold [20]. To examine this age group, we

323	stratified the 1,906 6-9 year-old children sampled into those 6-7 years of age (N=1,075),
324	representing 54% of children examined. Thus, there would be approximately 24,000 6-7 year of
325	age children in ENBP (Table 1; $45,188 \ge 0.54 = 24,400$). Using a community-based TAS
326	algorithm of a population size of ~20,000, the sample size would be ~1,500 in 30 clusters, like
327	the current baseline survey. Based on all 6-7 year-old children surveyed in 49 clusters, CFA
328	prevalence was 2.1% (95% CI 1.69-2.40, 22/1075), and none were Mf positive. In the 30
329	community-based clusters selected by PPS, the CFA prevalence in 6-7-year-olds was 0.6% (95%
330	CI 0.2-1.6%, 4/625), below the 2% CFA threshold, although this sample size is smaller than
331	WHO recommendation, yet the upper 95% CI is <2%. Thus, using the standard TAS survey
332	might have led to an erroneous conclusion that ENBP would not need MDA.

333

Table 2. Study population demographic and infection characteristics of 6-9 and ≥ 10 years
before MDA.

336 a. 6-9 years

District	*Total population	Villages surveyed	N	Percent Females	CFA+ (N)	CFA % (95%CI) [range]	Mf+ (N)	Mf % (95%CI) [range]	Villages ≥2% CFA	Villages ≥1% Mf
Kokopo	10,939	11	480	47	23	4.8 (3.1-7.1) [0-21.6]	5	1.0 (0.3-2.4) [0-7.8]	3	2
Gazelle	20,396	17	660	51	10	1.5 (0.7-2.8) [0-6.0]	0	-	5	-
Pomio	10,437	17	581	45	4	0.7 (0.2-1.8) [0-7.2]	0	-	3	-
Rabaul	3,415	4	185	52	0	-	0	-	-	-
Total	45,188	49	1,906	48	37	1.9 (1.4-2.7) [0-21.6]	5	0.3 (0.1-0.6) [0-7.8]	11	2

*The estimated population of 6-9-year-olds in ENBP according to the population pyramid rate for PNG.

338 b. ≥ 10 years

District	*Total population	Villages surveyed	Ν	Percent Females	CFA+ (N)	CFA % (95%CI) [range]	Mf+ (N)	Mf % [range]	Villages ≥2% CFA	Villages ≥1% Mf
Kokopo	69,284	11	477	66	46	9.6 (7.2-12.7) [0-52.0]	24	5.0 (3.3-7.4) [0-36.0]	6	3
Gazelle	129,174	17	827	58	30	3.6 (2.5-5.1) [0-15.7]	6	0.7 (0.3-1.6) [0-6.1]	8	3
Pomio	66,104	17	827	62	96	11.6 (9.5-14.0) [0-36.8]	16	1.9 (1.1-3.1) [0-5.8]	12	9
Rabaul	21,627	4	215	64	4	1.9 (0.5-4.7) [0-4.9]	1	0.5 (0.0-2.6) [0-2.4]	2	1
Total	286,190	49	2,346	61	176	7.5 (6.5-8.6) [0-52.0]	47	2.0 (1.5-2.7) [0-36.0]	28	16

339 The estimated population of \geq 10-year-olds in ENB according to the population pyramid rate for PNG.

340



LF infection in ENBP was highly heterogeneous, with the highest prevalence concentrated in the
Duke of York Islands (DOY) in the Kokopo district and Wide Bay Area along the eastern coast

of the Pomio District (Figure 3). Gazelle and Rabaul Districts had lower LF infection

353 prevalence.

354



355

Figure 3. Spatial distribution of lymphatic filariasis circulating antigen positivity (CFA, left panel) and
microfilaremia rates (Mf, right panel) throughout ENBP before mass drug distribution. Small solid dots
indicated communities without any detectable LF infection. The colors and circle size represent LF
prevalence for CFA or Mf.

360

361 Effect of sampling design for detecting LF infected villages

362 Sampling protocols affected the efficiency of detecting LF infection. In the 30 villages sampled

363 by PPS, 2.3% (95% CI 1.8-2.9%; 59/2,561) were CFA positive, and 0.6% (95% CI 0.3-0.9%;

14/2,561) were Mf positive. In children 6-9 years of age in the 30 villages selected by PPS, only 364 0.7% (95% CI 0.3-1.4; 8/1,121) were CFA positive, and none were Mf positive. Nine of 30 365 (30%) PPS selected villages had CFA >2%. (Figure 5 and Supplemental Table 4). Infection in 366 children and adults in the purposively selected villages was higher than in randomly selected 367 villages (Figure 5, Supplemental Table 5). The five original purposively selected villages had 368 369 >2% CFA positive, and 3 had Mf prevalences of >1% (Figure 5). Of the additional 14 villages purposely selected in rural villages, 10 (71.4%) villages had \geq 2% CFA, and 4 of 14 (28.6%) had 370 371 >1% Mf prevalence.



Figure 5. LF infection parameters are shown according to different sampling strategies for cluster selection. Thirty clusters used a population proportion random sample. ENBP Provincial Health Authority purposefully selected five additional clusters with prior evidence of LF. Fourteen more clusters were chosen to adequately sample rural areas in Pomio (N=9) and Gazelle (N=5) districts. The dashed line on the left panel and the red line on

the right panel represent WHO-specified thresholds of 2% CFA and 1% MF rates, suggesting ongoing
transmission in the cluster if above these thresholds.

383

384 Mass drug administration

The first round MDA was administered by the ENBP Provincial Health Authority in
November 2019 with the support PNG National Department of Health and Japan International

Cooperative Agency (JICA) to 307,568 of 376,566 total residents of ENBP (81.7%, reported or 387 administrative coverage), Supplemental Table 6). The reported coverage varied by district; 388 from rural districts of Pomio (72.8%) and Gazelle (83.8%) to 93.3% and 96.7% coverage in the 389 more urban districts of Kokopo and Rabaul, respectively. Of note, only DEC plus Albendazole 390 was administered to children 2 to 4. In December 2019, an independent coverage survey was 391 392 performed to validate the administrative coverage survey. This included 2,598 individuals in 450 randomly selected households in 45 randomly selected villages. Over 80% of the individuals 393 reported taking treatment in all age groups except those >50 years of age (supplemental Figure 394 395 1). Reported MDA compliance was equivalent in males and females and >80% in males 21-30 years (with the highest baseline LF prevalence). The most common reason for not taking the 396 drugs was absenteeism in all 4 districts. Residents of Rabaul also reported insufficient LF 397 awareness and incorrect age classification, which sometimes led to the exclusion of individuals > 398 55 years of age. 399

400

401 Model-Based geospatial sampling post-MDA LF infection parameters

Because the pre-MDA population proportionate sampling oversampled urban areas with 402 lower LF prevalence and under-sampled rural areas with higher LF prevalence, we undertook a 403 404 sampling strategy to reflect better the geographical distribution of LF in ENBP. Thus, we used model-based geospatial (MBG) as an alternative method to select clusters for monitoring and 405 evaluation during the post-MDA 1-year follow-up survey. Circulating filarial antigen (CFA) 406 407 prevalence data from the baseline survey was used to assess the risk probability for LF in ENBP (Figure 6). Besides location, the model considered the following covariates: relative humidity 408 409 (RH), annual precipitation (AP), annual temperature (AT), elevation (E), distance from the sea

(DS), and socio-economic status (SEI). Because of the small sample size, we combined the 410 covariates into a single covariate using principal component analysis (PCA) and used the first 411 component (PCA1) as a predictor for LF. More specifically, RH - 0.053, AP - 0.502 gave this 412 AT + 0.502 E+ 0.502 DS and explained about 62% of the total variation in the environmental 413 variables. The sample size was too small to establish which variables were most informative for 414 415 predicting areas with $\geq 2\%$ CFA. A hotspot area with an estimated prevalence above $\geq 2\%$ is identified in the central part of the eastern coast and in Duke of York Islands. The model selected 416 50 villages for sampling across the four districts of ENBP that were likely to have >2% of CFA 417 positivity using baseline LF data and co-variates associated with the presence of LF. Among the 418 50 sites, the model captured all 24 baseline clusters with >2% CFA and selected 26 not sampled 419 in the baseline survey. 420

421



Figure 6. Geospatial probability map of LF prevalence. The dark red area has a low probability that CFA prevalence is <2%; thus, these areas are more likely to have LF. The map resolution is 1 km. White areas have insufficient data to assess LF risk. Risk mapping was generated based on covariates of elevation, rainfall, temperature, distance from the sea, socioeconomic status, and LF prevalence using baseline survey clusters (black dots).

434	Of the 50 clusters selected, 47 were surveyed, with 4,611 participants from 6-9 and \geq 18-year-
435	old age groups, to capture Mf-positive individuals (Table 1) better. Geostatistical modeling
436	selected the 24 villages with >2% CFA identified pre-MDA (Table 1, supplemental Table
437	7). Following MDA-IDA, 20 of 23 newly selected villages had >2% CFA, indicating an
438	efficient selection of communities using MBG. Children were surveyed in 19 of the 47
439	clusters, and adults (≥18 years) were studied in all 47. Because of the differences in sampling
440	design pre- and post-MDA, we focused on changes in LF infection parameters in age-
441	matched groups in the 24 clusters monitored pre- and post-MDA in children and adults. In the
442	24 sentinel sites matched pre- and post-MDA for individuals ≥ 18 years of age, the CFA mean
443	prevalence decreased by 38.6% from 17.3% (95% CI 16.2-18.4; 141/816) to 10.6% (95% CI
444	10.1-11.2; 215/2,015; P<0.0001). By contrast, Mf prevalence decreased by 90.1% from 4.9%
445	(95% CI 4.28-5.52; 40/816) to 0.45% (95%CI 0.2-0.8; 9/2016, P<0.0001) (Figure 7). Eleven
446	of the 24 villages had children 6-9 years with LF infection before MDA, and 6-9 years old
447	were re-evaluated in these same villages post-MDA. CFA prevalence decreased by 30.1%
448	from a CFA prevalence of 7.2% (95% CI 4.8-10.5; 30/417) to 4.9% (95% CI 3.0-7.7; 18/365,
449	P=0.23). MDA completely cleared Mf infection in children from a prevalence of 1.2% (95%
450	CI 0.4-2.7; 5/417) to 0% (95% CI 0.0-1.0; 0/365; P=0.065).



Figure 7. Impact of treatment on CFA and Mf prevalence in 24 clusters before and after MDA. Individuals shown are ≥18 years old with N=816 before MDA and N=2015 12 months post-MDA. Dashed lines represent means.

Children 6-9 years in 8 additional villages were examined for LF infection parameters postMDA combined with 11 villages described above for a total 19. Post-MDA CFA prevalence
in children 6-9 years (in 19 villages) was 2.9% (95% CI 1.8-4.2; 20/694) was comparable to
1.9% (95% CI 1.4-2.7; 37/1,906; P=0.17) among children pre-MDA (**Table 2a**), further
demonstrating little change in CFA prevalence one-year post-MDA. By contrast, no Mfpositive children were identified post-MDA (0/694) compared to 0.3% pre-MDA (5/1,906; **Table 2a**).

- 464 Overall, post-MDA-IDA \geq 18-year-old CFA prevalence of 9.0% (95% CI 8.1-10.0;
- 465 352/3,916, **Table 3b**) was comparable to pre-MDA CFA prevalence among the same age
- 466 group of ≥ 18 years of 9.6% (95% CI 8.2-11.1; 151/1,581; supplemental table 2e). By
- 467 contrast, MDA-IDA markedly reduced overall Mf prevalence to 0.33% (95% CI 0.21-0.42;
- 468 15/4611). Two districts, Rabaul and Gazelle, had no sentinel villages with $\geq 1\%$ Mf positivity.
- However, 6 sentinel villages had $\geq 1\%$ Mf. Three clusters $\geq 1\%$ Mf occurred in the Duke of
- 470 York Islands (Kabatira, Karawara, and Utuan, 1%, 2% and 7% respectively) and the
- 471 remainder of the sentinel sites in the Kokopo district were Mf negative (Figure 8). The other

472 3 clusters with $\geq 1\%$ Mf positivity post-MDA were clustered along the East Coast in the Wide





Figure 8. Geographic distribution and prevalence of clusters sampled following MDA. The left panel
shows CFA prevalence, and the right panel shows Mf prevalence. Small white dots are clusters without
detectable CFA or Mf in participants. The color gradient of the maps corresponds to the different CFA
prevalence (left panel). The size of green circles correlates with Mf prevalence, with the smallest green
circles being 1% Mf.

489

490

492 Table 3. Study population demographic and infection characteristics of 6-9 and \geq 18 years

493 at 1 year-post MDA.

494 a. 6-9 years

District	Villages surveyed	N	Percent Females	CFA+ (N)	CFA % (95%CI) [range]	Mf+ (N) [range]	Mf %	Villages ≥2% CFA	Villages ≥1% Mf
Kokopo	5	231	50.7	9	3.9 (1.8-7.3) [0-10.6]	0	-	2	0
Gazelle	2	93	52.9	1	1.1 (0.0-5.9)	0	-	1	0
Pomio	12	370	46.6	10	2.7 (1.3-4.9)	0	-	5	0
Rabaul	0	0		-	-		-	-	-
Total	19	694	48.8	20	2.9 (1.8-4.4)	0		8	0

495

496 **b.** ≥18 years

District	Villages surveyed	N	Percent Females	CFA+ (N)	<i>CFA % (95%CI)</i> [range]	Mf+ (N)	<i>Mf</i> % [range]	Villages ≥2% CFA	Villages ≥1% Mf
Kokopo	9	627	64.9	91	14.5 (11.9-17.6) [0-58.2]	10	1.6 (0.8-2.9) [0-12.7]	8	3
Gazelle	12	1,107	54.2	34	3.1 (2.1-4.3) [0-18.7]	0	0.1 (0.0-0.1) [0.9]	9	0
Pomio	25	2,083	55.8	227	10.9 (9.6-12.4) [0-28.4]	5	0.3 (0.1-0.5) [0.9-1.0]	22	3
Rabaul	1	99	57.6	0	0	0	0	0	0
Total	47	3,916	56.84	352	9.0 (8.1-10.0) [0-58.2]	15	0.4 (0.2-0.6) [0-12.7]	39	6

498 Discussion

499	East New Britain was the first treatment province in PNG to implement MDA with
500	IDA. The program was highly successful and achieved >80% drug coverage after the first
501	round of MDA. Following one round of MDA, overall Mf prevalence decreased from 1.2%
502	pre-MDA to 0.3%, well below the WHO pre-TAS Mf prevalence target of $<1\%$. However,
503	some areas with high prevalence at baseline failed to reach this target. One of the four
504	districts in the province detected no Mf-positive individuals, and another district one Mf-
505	positive individual following MDA-IDA, suggesting little risk of ongoing LF transmission.
506	By contrast, 6 of 47 villages surveyed had post-MDA Mf prevalence $\geq 1\%$, indicating ongoing
507	risk for LF transmission in these areas. These remaining Mf-positive communities were
508	clustered in small geographic areas with high LF prevalence pre-MDA. Current WHO
509	guidelines recommend another round of MDA for the whole province [14], which has the
510	advantage of treating other parasitic infections or capturing Mf carriers from nearby
511	unsampled villages.

512 This study highlights the strengths and weaknesses of different sampling strategies and endpoints to assess LF prevalence where infections are highly focal and prior information 513 on LF is limited. The population proportional sampling strategy (PPS, WHO recommended) 514 used at baseline underestimated the LF burden. This is because PPS oversampled 515 516 communities in urban areas with little LF and under sampled communities in rural areas with 517 more LF. Results from this study also add to recent reports that highlight the limitations of TAS of young school-aged children for post-MDA stopping decisions. Before MDA, only 518 519 0.7% of children 6-9 years of age in ENBP were CFA positive, and 0.6% among children 6-7 years old, the TAS target population, which is well below the 2% threshold believed to 520

suggest recent or ongoing LF transmission. Indeed, ENBP probably could have passed TAS 521 522 performed according to WHO protocols before any MDA, even though the province had areas with high endemicity at that time. Since only a few infections in young children were detected 523 before MDA, TAS would have provided unreliable information for MDA-stopping decisions 524 following MDA. Despite low infection prevalence in children, ENBP was known to be 525 526 endemic for LF based on prior surveys conducted by health officials and confirmed by baseline surveys reported here. However, many other areas in PNG do not have detailed 527 information on LF prevalence because LF testing and reporting are not included in the 528 529 country's National Health Information Surveillance System. Our results from ENBP suggest that PPS and TAS may not be the best way forward for LF elimination efforts in other regions 530 in PNG. 531

This study reinforced the difficulty of using CFA alone as an endpoint for assessing 532 the impact of IDA on LF transmission. One round of MDA reduced CFA prevalence by 533 534 30.1% in children 6-9 years of age and 38.6% in adults; this lower CFA reduction in adults has been observed in prior clinical trials [8, 9, 11-13]. However, worms that survive IDA 535 treatment can continue to release CFA for years after Mf clearance [9]. One approach to this 536 537 problem for MDA-stopping decisions and post-MDA surveillance is to use CFA as a screening test in adults, with Mf testing restricted to those with positive antigen tests. It 538 539 should be safe to stop MDA if Mf prevalence has been reduced to very low levels in adults despite CFA prevalence >2%. Mosquitoes cannot transmit LF without access to Mf. 540 We used geospatial modeling to more efficiently identify communities at risk for LF 541 542 and assess the impact of one round of MDA. Geospatial modeling is increasingly used for

543 mapping tropical diseases in low-resource settings where disease distribution data are limited

544	or non-existent [21]. It incorporates information on known environmental and
545	sociodemographic risk factors for LF, including elevation, vegetation, and population density.
546	It has been increasingly used to map tropical diseases, such as malaria, Chagas disease, LF,
547	and trachoma [22-24] [25]. The method has also been applied to predict residual LF hotspots
548	post-MDA. Our results show that geospatial modeling was more helpful than PPS for
549	identifying communities with high CFA post-MDA using baseline infection data and
550	environmental variables. By facilitating the detection of persistent infections, this approach
551	should help inform programmatic decisions [26]. Because of the small sample size, the
552	analysis could not identify individual factors in the model most predictive of LF infection.
553	Prior WHO recommendations that stopping decisions for MDA based on the mean
554	prevalence in an EU is insufficient. As LF transmission approaches interruption, the
555	remaining LF infection becomes increasingly focal, and these foci should be targeted for
556	possible further MDA-IDA. This study highlights the concept. One round of MDA-IDA with
557	high coverage likely eliminated LF transmission in two of four districts in ENBP with low
558	baseline LF prevalence. Additional rounds of MDA-IDA could target the two districts with
559	clusters that have >1% Mf, or focus on clusters within the district, e.g. the Duke of York
560	Islands. The WHO recommends two rounds of MDA-IDA, which may capture those who
561	missed the first round of MDA and further treat other infections. However, in LF-endemic
562	areas like PNG, where LF infection may be highly focal, MDA costly, a single round of
563	MDA-IDA that achieves >80% coverage, the IDA impact survey could occur after the first
564	round of MDA. This would allow additional rounds of MDA-IDA to target areas with $>1\%$
565	Mf prevalence.

566	Several limitations should be mentioned regarding this study. Before MDA, we
567	sampled many children so that the median age of our sample was 12 years. In contrast, our
568	post-MDA survey focused more on adults (median age of 29 years). Since LF is age-
569	dependent, a direct comparison of infection prevalence before and after MDA required a
570	comparison of an age-matched subset of individuals sampled before and after MDA. Another
571	limitation of the study is that it only assessed the impact of one round of MDA, although
572	WHO recommends two rounds. This was intentional because we wanted to determine
573	whether a single round of MDA with high coverage would reduce Mf prevalence to <1%.
574	This did occur in many areas, but hotspots remained.
575	In conclusion, this study showed that a single round of MDA-IDA effectively reduced
576	Mf prevalence to very low levels in most endemic localities in ENBP. This was due to the
577	excellent efficacy of IDA in clearing Mf in PNG and the high MDA coverage provided by
578	public health officials in ENBP. Additional surveys will be needed to determine whether a
579	second round of MDA-IDA has been sufficient to clear up remaining hot spots of infection.
580	Results from this study will support the expanded use of IDA for LF elimination in
581	logistically challenging areas with significant resource limitations. They also clearly
582	demonstrated the importance of sampling adults rather than young children post-MDA and
583	the value of geospatial modeling for identifying high risk locations better to target monitoring
584	and evaluation efforts for LF elimination programs.
585	
586	Acknowledgments

587 We thank the staff of the East New Britain Provincial Health Authority and Papua New588 Guinea National Department of Health. In addition, we thank the teams who undertook the

589	sampl	e collections. We also thank the regional health directors, village leaders, and especially
590	our st	udy participants. The Bill & Melinda Gates Foundation (OPPGH5342 to GW and PF)
591	funde	d the project.
592		
593	Conti	ributors
594	KB, E	BM, CB, DT, MS, GW, PF, LR, ML, and CK were responsible for the study design. KB
595	perfor	med a literature search. KB, CB, MP, DT, and MS collected data; KB, DT, JK, EG, GW,
596	PD, a	nd CK analyzed and interpreted the data. KB and CK wrote the manuscript, which was
597	revise	d by GW and PF.
508		
220		
599	Refer	ences
600	1.	Nutman, T.B., Insights into the pathogenesis of disease in human lymphatic filariasis.
601		Lymphat Res Biol, 2013. 11(3): p. 144-8.
602	2.	WHO, Progress Report 2000-2009 and Strategic Plan 2010-2020, in Global Programme
603		to Eliminate Lymphatic Filariasis. 2010, WHO.
604	3.	WHO. Lymphatic filariasis: Key facts. 2020 [cited 2021 4/27/2021]; Available from:
605		https://www.who.int/news-room/fact-sheets/detail/lymphatic-
606		filariasis#:~:text=893%20million%20people%20in%2049,and%20incapacitated%20by%
607		20the%20disease.
608	4.	null, n., The roadmap towards elimination of lymphatic filariasis by 2030: insights from
609		quantitative and mathematical modelling [version 1; peer review: 2 approved]. Gates
610		Open Research, 2019. 3 (1538).

611	5.	Lymphatic filariasis - managing morbidity and preventing disability: An aide-mémoire
612		for national programme managers, Second edition. 2021, World Health Organization:
613		Geneva.
614	6.	Stolk, W.A., et al., Prospects for elimination of bancroftian filariasis by mass drug
615		treatment in Pondicherry, India: a simulation study. Journal of Infectious Diseases, 2003.
616		188 (9): p. 1371-81.
617	7.	WHO, Global programme to eliminate lymphatic filariasis: progress report, 2021, in
618		Weekly epidemiological record. 2022, World Health Organization Geneva.
619	8.	King, C.L., et al., A Trial of a Triple-Drug Treatment for Lymphatic Filariasis. N Engl J
620		Med, 2018. 379 (19): p. 1801-1810.
621	9.	King, C.L., G.J. Weil, and J.W. Kazura, Single-Dose Triple-Drug Therapy for
622		<i>Wuchereria bancrofti - 5-Year Follow-up</i> . N Engl J Med, 2020. 382 (20): p. 1956-1957.
623	10.	Thomsen, E.K., et al., Efficacy, Safety, and Pharmacokinetics of Coadministered
624		Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian
625		<i>Filariasis</i> . Clin Infect Dis, 2016. 62 (3): p. 334-41.
626	11.	Laman, M., et al., Mass drug administration of ivermectin, diethylcarbamazine, plus
627		albendazole compared with diethylcarbamazine plus albendazole for reduction of
628		lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial. Lancet
629		Infect Dis, 2022. 22(8): p. 1200-1209.
630	12.	Jambulingam, P., et al., An open label, block randomized, community study of the safety
631		and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs.
632		diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop
633		Dis, 2021. 15 (2): p. e0009069.

634	13.	Bjerum, C.M., et al., Efficacy and Safety of a Single Dose of Ivermectin,
635		Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Cote
636		d'Ivoire: An Open-label Randomized Controlled Trial. Clin Infect Dis, 2020. 71(7): p.
637		e68-e75.
638	14.	Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic
639		Filariasis 2017, Geneva: World Health Organization.
640	15.	Transmission assessment surveys in the Global Programme to Eliminate Lymphatic
641		Filariasis: WHO position statement. Wkly Epidemiol Rec, 2012. 87(48): p. 478-82.
642	16.	Organization, W.H., Monitoring Drug Coverage for Preventive Chemotherapy. 2010,
643		WHO: Geneva.
644	17.	Weil, G.J., et al., The impact of repeated rounds of mass drug administration with
645		diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea.
646		PLoS Negl Trop Dis, 2008. 2 (12): p. e344.
647	18.	Chipeta, M.G., et al., Adaptive geostatistical design and analysis for prevalence surveys.
648		Spatial Statistics, 2016. 15: p. 70-84.
649	19.	Giorgi, E. and P.J. Diggle, PrevMap: An R Package for Prevalence Mapping. 2017,
650		2017. 78 (8): p. 29.
651	20.	WHO. Lymphatic filariasis: monitoring and epidemiological assessment of mass drug
652		administration A manual for national elimination programmes, in Lymhatic Filariasis,
653		2011, WHO: Geneva.
654	21.	Diggle, P.J. and E. Giorgi, Model-based geostatistics for global public health: Methods
655		and application Interdisciplinary Statistic Series, ed. N. Keidling, et al. 2019: CRC Press.

- Eneanya, O.A., et al., *Mapping the baseline prevalence of lymphatic filariasis across*
- 657 *Nigeria*. Parasites & Vectors, 2019. **12**(1): p. 440.
- 658 23. Mwase, E.T., et al., *Mapping the Geographical Distribution of Lymphatic Filariasis in*
- *Zambia*. PLOS Neglected Tropical Diseases, 2014. **8**(2): p. e2714.
- 660 24. Slater, H. and E. Michael, Mapping, Bayesian Geostatistical Analysis and Spatial
- 661 *Prediction of Lymphatic Filariasis Prevalence in Africa*. PLOS ONE, 2013. **8**(8): p.
- 662 e71574.
- 663 25. Diggle, P.J., et al., *Rethinking neglected tropical disease prevalence survey design and*
- 664 *analysis: a geospatial paradigm.* Transactions of The Royal Society of Tropical
- 665 Medicine and Hygiene, 2021. **115**(3): p. 208-210.
- 666 26. Mayfield, H.J., et al., *Supporting elimination of lymphatic filariasis in Samoa by*667 *predicting locations of residual infection using machine learning and geostatistics.*
- 668 Scientific Reports, 2020. **10**(1): p. 20570.